IRIS
GIULIANO, MARIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.667
EU - Europa 3.705
NA - Nord America 3.389
SA - Sud America 622
AF - Africa 108
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 3
Totale 12.501
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.236
SG - Singapore 2.462
RU - Federazione Russa 1.825
CN - Cina 1.125
IT - Italia 924
BR - Brasile 500
HK - Hong Kong 391
VN - Vietnam 361
DE - Germania 247
NL - Olanda 148
IN - India 112
FI - Finlandia 98
GB - Regno Unito 97
CA - Canada 84
FR - Francia 79
IE - Irlanda 59
AR - Argentina 58
KR - Corea 56
MX - Messico 44
SE - Svezia 44
CI - Costa d'Avorio 42
PL - Polonia 34
ZA - Sudafrica 31
UA - Ucraina 30
ES - Italia 26
AT - Austria 22
BD - Bangladesh 22
BE - Belgio 18
IQ - Iraq 17
JP - Giappone 17
EC - Ecuador 16
PK - Pakistan 15
ID - Indonesia 12
VE - Venezuela 10
CZ - Repubblica Ceca 9
CO - Colombia 8
PY - Paraguay 8
TR - Turchia 8
UZ - Uzbekistan 8
CL - Cile 7
MA - Marocco 7
AE - Emirati Arabi Uniti 6
MY - Malesia 6
PE - Perù 6
IR - Iran 5
LT - Lituania 5
PS - Palestinian Territory 5
RS - Serbia 5
UY - Uruguay 5
AU - Australia 4
DZ - Algeria 4
IL - Israele 4
KZ - Kazakistan 4
AL - Albania 3
BW - Botswana 3
BY - Bielorussia 3
BZ - Belize 3
DK - Danimarca 3
DO - Repubblica Dominicana 3
HN - Honduras 3
JM - Giamaica 3
MN - Mongolia 3
NP - Nepal 3
NZ - Nuova Zelanda 3
PA - Panama 3
PH - Filippine 3
SA - Arabia Saudita 3
AM - Armenia 2
BB - Barbados 2
BF - Burkina Faso 2
BG - Bulgaria 2
BO - Bolivia 2
BS - Bahamas 2
CH - Svizzera 2
CR - Costa Rica 2
EG - Egitto 2
GR - Grecia 2
GT - Guatemala 2
HR - Croazia 2
IS - Islanda 2
JO - Giordania 2
KE - Kenya 2
KG - Kirghizistan 2
KH - Cambogia 2
MD - Moldavia 2
MG - Madagascar 2
MK - Macedonia 2
NG - Nigeria 2
NO - Norvegia 2
PT - Portogallo 2
SD - Sudan 2
SK - Slovacchia (Repubblica Slovacca) 2
TN - Tunisia 2
TW - Taiwan 2
XK - ???statistics.table.value.countryCode.XK??? 2
AF - Afghanistan, Repubblica islamica di 1
AZ - Azerbaigian 1
BH - Bahrain 1
ET - Etiopia 1
EU - Europa 1
Totale 12.479
Salva come PNG Salva come JPEG
Città #
Singapore 1.155
Moscow 454
Chandler 426
Hong Kong 390
Hefei 349
Beijing 330
Ashburn 298
Naples 202
Santa Clara 196
Napoli 127
Amsterdam 125
Dallas 119
Millbury 113
Los Angeles 109
Ho Chi Minh City 108
Munich 93
Hanoi 68
San Jose 66
Buffalo 64
New York 64
Princeton 55
Kochi 54
Seoul 54
Des Moines 52
Redondo Beach 49
São Paulo 47
Turku 43
Boston 41
Nanjing 41
The Dalles 38
Wilmington 37
Dong Ket 36
Lawrence 34
Seattle 28
Pune 26
Rome 26
Warsaw 26
Nuremberg 25
Orem 25
Ottawa 25
Milan 24
Montreal 24
Mexico City 23
Frankfurt am Main 22
Denver 21
Toronto 21
Stockholm 20
Poplar 19
Brooklyn 18
Jacksonville 18
London 18
Rio de Janeiro 18
Haiphong 17
Chicago 15
Houston 15
Tokyo 15
Johannesburg 14
Belo Horizonte 13
Biên Hòa 13
Casoria 13
Da Nang 13
Formia 13
Pomigliano d'Arco 13
Tianjin 13
Boardman 12
Brussels 12
Dearborn 11
Helsinki 11
Nanchang 11
Vienna 11
Atlanta 10
Falkenstein 10
Hải Dương 10
Ninh Bình 10
Porto Alegre 10
Shenyang 10
Woodbridge 10
Changsha 9
Jiaxing 9
Manchester 9
Shanghai 9
Villaricca 9
Caserta 8
Charlotte 8
Chennai 8
Curitiba 8
Guangzhou 8
Hebei 8
Lauterbourg 8
Phoenix 8
Redwood City 8
Baghdad 7
Bologna 7
Brasília 7
Dublin 7
Fairfield 7
Genoa 7
Guayaquil 7
Kronberg 7
Salerno 7
Totale 6.349
Salva come PNG Salva come JPEG
Nome #
Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology. 159
Metabolic and anthropometric changes in early breast cancer patients receiving adjuvant therapy 153
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: A survey of young oncologists 152
CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors. 149
Impaired Seroconversion After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA Vaccine in Patients With Thymic Epithelial Tumors 146
Epigenetic silencing of THY1 tracks the acquisition of the Notch1-EGFR signaling in a xenograft model of CD44+/CD24low/CD90+ myoepithelial cells 145
The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer 141
A New Horizon of Liquid Biopsy in Thymic Epithelial Tumors: The Potential Utility of Circulating Cell-Free DNA 138
The Never-Ending History of Octreotide in Thymic Tumors: A Vintage or A Contemporary Drug? 134
Prevalence of Sarcopenia in Women with Breast Cancer 133
Strain-oriented strategy for guiding cardioprotection initiation of breast cancer patients experiencing cardiac dysfunction 127
Shifting from a Biological-Agnostic Approach to a Molecular-Driven Strategy in Rare Cancers: Ewing Sarcoma Archetype 125
Bowel obstruction and peritoneal carcinomatosis in the elderly. A systematic review 124
Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients 124
Combined effect of obesity and diabetes on early breast cancer outcome: A prospective observational study 123
Safety and immunogenicity of the COVID-19 vaccine BNT162b2 for patients with breast and gynecological cancer on active anticancer therapy: Results of a prospective observational study 122
Optimising triage procedures for patients with cancer needing active anticancer treatment in the COVID-19 era 122
R0 surgical resection of giant dedifferentiated retroperitoneal liposarcomas in the COVID era with and without nephrectomy: A case report 121
Systemic treatment of malignant gastrointestinal neuroectodermal tumour after childhood neuroblastoma: chemotherapy in malignant gastrointestinal neuroectodermal tumour 120
Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study 120
Extraskeletal Ewing's sarcoma of the mediastinum: Case report 119
Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial 118
Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series 118
Long-term survival and BRCA status in male breast cancer: A retrospective single-center analysis 116
Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis 116
Tumor characteristics and prognosis in familial breast cancer 115
Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI) 115
A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer 115
Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations 114
The Impact of Translational Research in Breast Cancer Care: Can We Improve the Therapeutic Scenario? 114
Body weight and risk of molecular breast cancer subtypes among postmenopausal Mediterranean women 113
Pretreatment Serum Concentration of Vitamin D and Breast Cancer Characteristics: A Prospective Observational Mediterranean Study 113
It is no longer the time to disregard thyroid metastases from breast cancer: A case report and review of the literature 113
Assessment of Total, PTEN–, and AR-V7+ Circulating Tumor Cell Count by Flow Cytometry in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide 113
Insight on the Role of Leptin: A Bridge from Obesity to Breast Cancer 112
Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis 112
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: An open-label, 2 × 2 factorial, randomised phase 3 trial 112
Heterogeneity of SSTR2 expression assessed by 68Ga-DOTATOC PET/CT using coefficient of variation in patients with neuroendocrine tumors 111
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype 110
Mechanisms of lapatinib resistance in HER2-driven breast cancer 109
Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results 108
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 108
Unexpected ovarian activity in premenopausal breast cancer survivors treated with exemestane and GnRH analogues 108
The Epithelial-Stromal Interaction as a Potential Target for Breast Cancer Treatment 107
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis 107
Tumori maligni del colon 106
Circulating tumor cells in newly diagnosed inflammatory breast cancer 105
Serum biomarkers of inflammation and vascular damage upon SARS-Cov-2 mRNA vaccine in patients with thymic epithelial tumors 104
Biological mechanisms and clinical implications of endocrine resistance in breast cancer. 104
Fractional microablative CO2 laser in breast cancer survivors affected by iatrogenic vulvovaginal atrophy after failure of nonestrogenic local treatments: a retrospective study 104
Long-Term Outcomes in Uveal Melanoma After Ruthenium-106 Brachytherapy 104
Central obesity, body mass index, metabolic syndrome and mortality in Mediterranean breast cancer patients 103
DLL3 as a potential diagnostic and therapeutic target in neuroendocrine neoplasms: A narrative review 103
Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials 103
Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients. 103
Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis. 103
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study 103
Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis 102
A djuvant treatment in patients at high risk of recurrence of thymoma: Efficacy and safety of a three-dimensional conformal radiation therapy regimen 102
Exploring the interplay between Kaposi's sarcoma and SARS‐CoV‐2 infection: A case series and systematic review 101
COVID-19 in patients with thymic epithelial tumors with or without Good's syndrome: a single-center retrospective study 101
Efficacy of PARP inhibitors in advanced high-grade serous ovarian cancer according to BRCA domain mutations and mutation type 101
Blockade of AP-1 potentiates endocrine therapy and overcomes resistance 101
Ten-year update of HOBOE phase III trial comparing triptorelin plus either tamoxifen or letrozole or zoledronic acid + letrozole in premenopausal hormone receptor-positive early breast cancer patients 100
Phase II trial of gemcitabine, prednisone, and zoledronic acid in pretreated patients with hormone refractory prostate cancer. 100
FOLFOX-4 in pre-treated patients with advanced transitional cell carcinoma of the bladder. 100
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase 100
Boosting the immune response with the combination of electrochemotherapy and immunotherapy: A new weapon for squamous cell carcinoma of the head and neck? 100
Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer. 98
Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications. 97
Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer 96
Corrigendum to 'Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)': [ESMO Open Volume 6, Issue 2, April 2021, 100054] 96
Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis 96
Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. 96
PI3K/mTOR Inhibitors in the Treatment of Luminal Breast Cancer. Why, When and to Whom? 96
Epigenetic control of gene expression: Potential implications for cancer treatment 95
Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671) 94
Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer. 94
Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. 94
Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination 94
Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives 94
The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancer 93
Mammary Adipose Tissue Control of Breast Cancer Progression: Impact of Obesity and Diabetes 92
Endocrine‐based treatments in clinically‐relevant subgroups of hormone receptor‐positive/her2‐negative metastatic breast cancer: Systematic review and meta‐analysis 92
Case report: Potential role of immunotherapy in thymic malignancies: a unique case of a durable and complete response upon an immune checkpoint inhibitor 91
Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. 91
Crosslink between atrial fibrillation and cancer: a therapeutic conundrum 90
Estrogen deprivation effects of endocrine therapy in breast cancer patients: Incidence, management and outcome 90
Warming-up the immune cell engagers (ICEs) era in breast cancer: state of the art and future directions 88
Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. 88
Immunological signature of patients with thymic epithelial tumors and Good syndrome 87
Genetics and management of locally advanced carcinomas of the head and neck: Role of altered fractionation radiotherapy 86
Ribociclib in newly diagnosed hepatitis B infection: A case report 85
Fine-Needle Aspiration Is Suitable for Breast Cancer BRCA Molecular Assessment: A Case Report 85
miRNAs in the Box: Potential Diagnostic Role for Extracellular Vesicle-Packaged miRNA-27a and miRNA-128 in Breast Cancer 84
Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time? 84
Neoadjuvant Versus Adjuvant Systemic Therapy in Breast Cancer: A Matched Case-control Study 82
New steps on an old path: Novel estrogen receptor inhibitors in breast cancer 82
Upregulation of ER signaling as an adaptive mechanism of cell survival in HER2-positive breast tumors treated with Anti-HER2 therapy 82
Optimal multidisciplinary treatment of oral cavity mucosal melanoma: Outcome analysis in a case series 79
Totale 10.738
Salva come PNG Salva come JPEG
Categoria #
all - tutte 42.047
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 42.047
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021172 0 0 0 0 0 0 28 13 49 17 20 45
2021/2022600 9 4 17 9 6 24 14 23 69 60 154 211
2022/20231.005 97 89 37 64 128 104 18 95 146 150 53 24
2023/2024787 33 120 96 51 42 102 11 75 23 24 130 80
2024/20254.212 168 176 14 104 125 224 419 242 350 485 1.566 339
2025/20265.182 893 668 965 836 1.346 405 69 0 0 0 0 0
Totale 12.774